How CJC-1295 and Ipamorelin Work in the Body

CJC-1295 and ipamorelin are two lab-made peptides that signal the pituitary gland to release more growth hormone (GH). CJC-1295 is a long-acting analog of growth hormone-releasing hormone (GHRH), and in healthy adults it raised GH and insulin-like growth factor 1 (IGF-1) for days after one injection.¹ Ipamorelin works through a second receptor and releases GH selectively in animal studies.² The blend itself has only animal data,³ and neither peptide is an approved drug.^4,8 If you are weighing it, your physician starts with your labs and a measurable goal.

Two Peptides on Two Pituitary Signals

The pituitary releases GH in response to more than one signal, and each peptide in the blend copies a different one. The two are sold together for that reason. Each was studied alone in people, so you get the clearest picture by looking at each one separately.

CJC-1295, a Long-Acting GHRH Analog

CJC-1295 is a synthetic version of GHRH, the hypothalamic hormone that tells the pituitary to make and release GH. Natural GHRH is short-acting, which limits its use as a treatment.¹ CJC-1295 binds to albumin, a blood protein, after injection, which gives it a half-life of about eight days.⁵ In the Teichman trials, the estimated half-life was 5.8 to 8.1 days.¹

Dominikowski A et al. list CJC-1295 with Drug Affinity Complex (DAC) and CJC-1295 without DAC as separate GHRH analogues.⁴ The human trials described on this page used the long-acting, albumin-binding molecule.^1,5 If you are offered a product, ask your prescriber which form it contains, because the published human data apply to that one form.

Ipamorelin, a Selective Ghrelin-Receptor Agonist

Ipamorelin is a five-amino-acid peptide that activates the ghrelin receptor, which Raun K et al. described as a GHRP-like receptor.^2,7 In swine, it released GH without raising follicle-stimulating hormone, luteinizing hormone, prolactin or thyroid-stimulating hormone. Unlike GHRP-6 and GHRP-2, it did not raise ACTH or cortisol above what GHRH alone produced.² Raun K et al. called it the first GHRP-receptor agonist with GH selectivity similar to GHRH.²

That selectivity is an animal finding. It tells your physician why ipamorelin was developed, and it is a starting hypothesis for how it might behave in you.

Human Trial Results for Each Peptide

Each peptide has been tested in people by itself, mostly for hormone levels over short periods. Those results show what the molecules do to GH and IGF-1. They do not show changes in muscle, fat or how you feel.

What the CJC-1295 Trials Measured

Teichman SL et al. ran two randomized, placebo-controlled, double-blind trials in healthy adults aged 21 to 61, lasting 28 and 49 days.¹ After a single injection, mean GH rose 2- to 10-fold for six days or more. Mean IGF-1 rose 1.5- to 3-fold for 9 to 11 days. With repeated doses, IGF-1 stayed above baseline for up to 28 days, and no serious adverse reactions were reported.¹

Ionescu M et al. sampled blood every 20 minutes overnight in healthy men aged 20 to 40, before and one week after a single injection.⁵ GH secretion rose while its natural pulses kept the same frequency and size. Trough GH rose 7.5-fold, mean GH rose 46% and IGF-1 rose 45%.⁵ The authors noted that long-acting GHRH products may be useful in people whose pituitary can still make GH.⁵

What the Ipamorelin Trials Measured

Gobburu JV et al. infused ipamorelin into healthy male volunteers at five dose levels, with eight men at each level.⁶ It had a terminal half-life of 2 hours. Each infusion produced a single GH pulse that peaked at about 40 minutes (0.67 hours) and then faded.⁶

A randomized phase 2 study tested ipamorelin in 117 hospital patients after bowel surgery for slow gut recovery, and its authors described it as small.⁷ Treatment-emergent adverse events occurred in 87.5% of the ipamorelin group and 94.8% of the placebo group. Ipamorelin did not differ from placebo on the efficacy measures.⁷ That trial adds short-course safety data from a hospital setting. For GH and IGF-1, the CJC-1295 and ipamorelin hormone trials above and your own follow-up IGF-1 are the reference points.

Evidence for the Combined Blend

The CJC-1295 and ipamorelin blend has been studied in mice. Mayfield CK et al. reported that the combination improved muscle force in mice with glucocorticoid-induced muscle loss, and they stated that the finding is limited to animal studies.³ The same review states that the indications, dosing, frequency and duration of treatment remain unknown.³

The rationale for pairing them is mechanistic: one peptide raises the GH baseline over days, and the other triggers short pulses. The combination has not been tested as a human outcome, so a plan that uses the blend should name in advance the lab marker or body-composition measure your physician will follow. For the sermorelin side of this question, see sermorelin vs ipamorelin and sermorelin vs CJC-1295.

Regulatory Status and Compounded Supply

Neither CJC-1295 nor ipamorelin is an approved drug, and Dominikowski A et al. note the absence of regulatory approval for physique or performance indications.⁴ A 2026 structured review classed both as investigational, with uncertain safety profiles and product-quality concerns, and advised confining clinical use of injectable peptides to approved agents for indicated conditions and to research protocols.⁸ Both are also restricted under sports antidoping rules.⁸ If a prescriber offers the blend outside a trial, ask which lab result will decide whether it stays in your plan.

FDA places bulk drug substances nominated for compounding in category 2 when its review of the nomination finds they may present substantial safety risks.¹¹ As of FDA's April 22, 2026 update, ipamorelin acetate sits in category 2 under the 503B interim policy, with a date added of September 29, 2023.¹¹ FDA also lists CJC-1295 and ipamorelin acetate among substances previously in category 2 whose nominations were withdrawn by the nominators.¹¹ For CJC-1295, FDA names possible immunogenicity, complexities with peptide-related impurities and serious adverse events including increased heart rate and a systemic vasodilatory reaction, and it calls the available clinical data limited.¹¹ For ipamorelin acetate, FDA names possible immunogenicity and a published report of serious adverse events, including death, when ipamorelin was given intravenously for gastric motility.¹¹ Your physician weighs that FDA record when reviewing whether any prescribed option is appropriate for you.

Dominikowski A et al. describe uncertainty about product composition and dose in unregulated supply chains.⁴ A research-labeled vial bought online carries that uncertainty. A compounded prescription from a licensed pharmacy is a different supply route, and the product-quality concern raised by Villegas Meza AD et al. still applies to it.⁸ You can ask your prescriber which pharmacy made it and how each batch is tested. Does it matter where you get your peptides covers that question in more depth.

Side Effects and Markers a Physician Follows

The side effects reported for GH-axis peptides as a group include prolactin and cortisol rises, appetite changes, blood sugar problems, fluid retention, muscle and joint aches, and injection-site reactions.⁴ That list covers the whole class, and the review does not assign each effect to one peptide.⁴ A review of GH secretagogues found them generally well tolerated, with some concern for rising blood glucose from lower insulin sensitivity.⁹

The same review noted that few long-term, rigorously controlled studies exist for the class.⁹ In hypogonadal men, data on clinical benefit are largely lacking.¹⁰ Your physician closes that gap with monitoring. IGF-1 was the main outcome in the CJC-1295 trials, and glucose is the safety signal the class review flagged, so both give your follow-up labs a clear target.^1,9

A Prescriber's Questions Before a Growth Hormone Peptide

A physician considering this blend for you works through a short list before writing anything:

• Your goal. A body-composition goal needs a body-composition measure. A vague goal leaves you no way to judge the result.
• Your baseline. Your IGF-1, glucose and broader hormone panel set the starting point.
• Your history. Current medications, diabetes risk and existing conditions change the risk side.
• The product. The CJC-1295 form, the pharmacy and the testing behind the vial.
• The stop rule. The lab or symptom change that ends or changes the plan.

The dose and schedule are set by your prescriber from those answers. If your goal is muscle, peptides for muscle growth and what peptides should I take compare the options, and HGH peptides covers the wider category.

The Opt Take on CJC-1295 and Ipamorelin

A growth hormone peptide is a lever on one hormone axis, and your first step is finding out whether that axis explains your symptoms. Low energy, slow recovery and stubborn fat have several possible drivers, including sleep, insulin, thyroid and sex hormones. One IGF-1 result read alone is a data point. Your physician reads it with the rest of the pattern.

At Opt Health, you start with a panel of 55+ biomarkers at home or at a partner lab, then a 1:1 review with an Opt Health physician. If your results and your goal raise the question of a growth hormone peptide, your physician reviews whether any prescribed option is appropriate for you. Full labs and a physician consultation repeat every 3 to 4 months, so your plan is adjusted on what your numbers did.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.

Frequently Asked Questions

This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.